Ketamine One (NEO:MEDI.AQN) Interim CEO Adam Deffett joined Steve Darling from Proactive to share news their wholly-owned contract research organization, KGK Science has secured four newly signed contracts with third-party clinical research and regulatory service clients.
Deffett telling Proactive this secures significant new business and the group of impending clients operates in the cannabis, food, non-profit and pharmaceutical sectors and are interested in exploring topics including Pharmacokinetics, cardiovascular, immunity as well as serum IGF-1 concentration.